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The recent threat which has received worldwide attention is COVID-19, a rapidly spreading new strain of Coronavirus. 
It has affected more than 176 countries and due to the lack of efficacious drugs or vaccines against SARS-CoV-2, it has 
further worsened the situation everywhere. After infecting the host, the ssRNA genome of SARS-CoV-2 is translated into a 
large polyprotein which will be further processed into different nonstructural proteins to form a viral replication complex by 
the virtue of virus-specific proteases namely main protease (3-CL protease) and papain protease. The crystallized form of 
SARS-CoV-2 main protease (Mpro) is demonstrated to be a novel therapeutic drug target according to current research. 
The present study was conducted to evaluate the efficacy of few plant-based bioactive compounds against COVID-19 Mpro 
(PDB ID: 6LU7: Resolution 2.16 Å) by molecular docking study. Molecular docking investigations were performed by 
using Auto DockVina to analyze the inhibition capacity of these compounds against COVID-19 as a whole complex and 
also in the absence of Chain C which is present with protein as a peptide. According to the obtained results, Ritonavir and 
Curcuminwere found to be more effective on COVID-19 than nelfinavir which is an anti-HIV drug. This is followed by 
Glycyrrhizin and Piperine, which correlates with COVID-19 as a whole complex and also in the absence of Chain C. So, 
this study will pave a way for performing more advanced experimental research and to evaluate the natural compounds to 
cure COVID-19. 
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Introduction 
Coronavirus infection was first identified in Wuhan 
in China in December 2019 which became the centre 
of a pneumonia outbreak of unknown cause
1
. In early 
January 2020, Chinese scientist pinpointed a novel 
Coronavirus strain from people of Wuhan which 
started at a local seafood/wild animal market
2
. Severe 
acute respiratory syndrome [SARS] associated with 
this disease was named 2019-nCOV, which is now 
named COVID-19
3
. Coronavirus is not a new virus, it 
was discovered in 1960 causing illness among 
animals including camels, cattle, cat, and bats. 
Transmission from animal to human was not reported 
until 2002. SARS outbreak and later in 2012 as 
MERS outbreak was due to transmission from animal 
to human confirmed transmission
4
. Coronavirus 
which is transmitted by respiratory droplet and 
contaminated surfaces is known to cause common 
colds. At present, there are a total of seven strains of 
human coronavirus which include alpha coronavirus 
[HCOV-229E; HCOV-NL63] and beta CORONA 
VIRUS [HCOV-OC43; HCOV-HKU1; SARS-COV-1; 
MERS-COV and now SARS-COV-2]
5
. The first 
reported International case in Thailand on 13 January 
2020 was transmitted by an infected person from 
Wuhan and slowly started spreading to other parts 
of the world. On 30 January 2020, the World Health 
Organization (WHO) emergency committee designated 
the novel coronavirus outbreak as Public health 
emergency of International concerns (PHEIC). After 6 
weeks (11.03.2020), WHO declared COVID-19 as 
pandemic
6
. People who have developed pneumonia 
due to SAR-COVwere characterized with a distinct 
lung appearance of ground glass opacity in specific 
shapes and sites as the severity of the disease 
progresses
7









infectious for up to 4 weeks, twice as long as most of 
the current quarantine measures. Health care 
professionals and others with close contact with these 
infected individuals should use standard, contact and 
airborne precaution and well as wear eye protection
8
. 
No vaccine is currently available to prevent COVID-
19 and evidence indicate that human Coronavirus may 
potentially remain infectious in the air for at least 3 
hours and on inanimate surfaces for 2-3 days up to 9 
days, and perhaps longer
9
. Viable SARS COVID 2 
RNA has been isolated from respiratory, blood, urine, 
and stool specimens
10
. The mainstay of treatment is 
supportive care. Various therapies are under 
investigation and under development which included 
antiviral drugs (lopinavir and ritonavir), immune-
modulators like interleukin-6 inhibitors (sarilumab), 
antimalarial (hydroxychloroquin), and corticosteroids. 
Lopinavir and Ritonavir, combined with Chinese 




In this connection, in silico technique was used to 
identify potential leads for the treatment for COVID-
19. The crystallized form of SARS-CoV-2 main 
protease (Mpro) is demonstrated to be a novel 
therapeutic drug target according to current research. 
The present study was conducted to evaluate the 
efficacy of few plant-based bioactive compounds 
against COVID-19 Mpro by molecular docking study 
against COVID-19. 
 
Materials and Methods 
The structures of the compounds were procured 
from the authors’ earlier research on plant-based 
isolation and characterization of drugs. 2D structures 
were analyzed in PubChemand PDB files of ligands 
were generated using OpenBabel software
13,14
. Energy 
minimization was carried out using PRODRG server 
and PDB file with known inhibitors were converted 
into PDBQT file format using Auto Dock Tool 
(ADT)[Autodock Vina] for further analysis
15
. 
The atomic coordinates of COVID-19 Mpro main 
were retrieved from the RCSB PDB (https:// 
www.rcsb.org/pdb/home/home.do). Before docking 
analysis, the structure was emended by removing co-
crystallized heteroatoms and water molecules using 
SPDBV software, followed by the addition of polar 
hydrogen and Gasteiger charges using Auto Dock 
Tool (ADT). Then structures were saved in PDBQT 
files, for further analysis. 
Binding mode and interaction of COVID-19 Mpro 
with ligands were performed using Auto dockVina on 
Ubuntu Linux platform
16
. This Program requires a 
pre-calculated grid box, which serves as a frontier  
of active pocket amino acids in the receptor by 
attaining XYZ coordinates. The active pocket  
amino acid residues were identified using PoSSuM 
server (http://possum.cbrc.jp/PoSSuM/). The grid 
optimization was carried out using the auto grid and 
the grid box was placed such that it covers all amino 
acids of an active pocket. The grid box size was set at 
16, 16, and16 and centred on mass centre 3.753, 
15.918, and 9.96 for x, y, and z co-ordinate 
respectively with space-separated by 1.0 Å (grid-point 
spacing). Docking was performed using Auto Dock 
program and ten different modes of conformations 
were generated with their respective binding 
energy/affinity. The lowest binding energy results 
were considered for further post docking analysis. 
Docked complex of protein and ligand with good 
binding affinity were visualized using maestro and a 
chimera. LigPlot 1.4.5 was used to generate a two-
dimensional docking for the analysis of hydrogen 




Results and Discussion 
Recently, COVID-19, a rapidly spreading new 
strain of Coronavirus has received worldwide 
attention. The first Indian case of COVID-19 was 
found in Kerala on 30 January 2020. There onwards 
the increase in the cases in India is given in Fig 1.  
It has affected more than 176 countries and due to the 
lack of efficacious drugs or vaccines against  
SARS-CoV-2, it has further worsened the situation 
everywhere. There was an increase in cases of 
COVID-19 from 1 to 4281 [06.04.2020] with 111 
death and 318 recovered patients. Whereas the total 
number of global cases was 1328150 with 73750 
death and 277285 recovered patients in the month of 
 
 
Fig. 1 — Number of COVID cases in India with confirmed, 
recoveries and death. 






 and presently as of 8.12.2020, the total 
number of global cases is 68,084,568 with 1,555,774 
deaths and 47,160,070 recovered patients
20
. 
In the present scenario as no treatment is available, 
so natural sources may come as a saviour for this 
deadly disease. Natural product treatment will be 
cheap and with fewer side effects. As per WHO, 80% 
of the world population relies on natural products for 
their ailments. In this connection, we have chosen 
plants that are frequently used in Indian cooking  
like Turmeric (Curcuma longa), Black pepper  
(Piper nigrum), Zinger (Zingiber officinale), Tulsi 
(Ocimum sanctum), Liquorice (Glycyrrhiza glabra),  
Kalonji (Nigella sativum) etc. The basis for choosing 
the phytoconstituents is their reported usage in 
respiratory, asthma and for immunity booster and 
numerous other disorders
21-26
. In silico modelling  
was done with azadirachtin, β-sitosterol, curcumin, 
gingerol, glycyrrhizin, piperine, quercetin, 
thymoquinone, ursolic acid against the synthetic drugs 
viz., hydroxychloroquine, lopinavir, nelfinavir, and 
ritonavir. 
The binding energies obtained and hydrogen bonds 
formed from the docking of 6LU7 are presented in 
Table 1. Ritonavir has formed 4 hydrogen bonds 
followed by Curcumin and Glycyrrhizin. In terms of 
binding energy also, these three require minimum 
energy [-6.4; -6.6 and -6.5 Kcal/mol] respectively and 
in turn, seem to be more efficient compared to other 
compounds. The standard drugs nelfinavir and 
hydroxychloroquine have formed 2 hydrogen bonds 
by using binding energy [-6.0 and -5.0 Kcal/mol] 
respectively slightly more than that of the above-
mentioned values. Fig 2 shows the superimposition  
of all ligands with COVID-19 Mpro whole complex. 
Fig 3 shows 2D interaction of ligands with amino 
acids of COVID-19 Mpro whole complex. Detailed 
hydrogen bond formation of the ligand with amino 
acids of COVID-19 Mpro whole complex of ligands 
showing best conformation (Curcumin, glycyrrhizin, 
ritonavir) are given in Fig. 4. 
Molecular docking investigations were performed 
by removing C Chain of COVID-19 as it is present as 
a peptide near the active site of the protein. The 
Table 1 — Showing binding energy and hydrogen bonds formed with COVID-19 Mpro whole complex and ligands. 
Ligands Affinity (Kcal/mol) H bonds H bond interaction  
Azadirachtin -5.4 - - 
Beta_Sitosterol -5.0 - - 
Curcumin -6.6 3 Cys 145(A); Ser 144(A); His 163(A) 
Gingerol -6.0 1 Cys 145 (A) 
Glycyrrhizin -6.5 2 Thr 24(A); Gln 189(A) 
Hydroxychloroquine -5.0 2 Cys 145 (A); Thr 24 (A) 
Lopinavir -6.4 2 2-Gln 189(A) 
Nelfinavir -6.0 2 - 
Piperine -5.9 1 Gly 143(A) 
Quercetin -5.8 - - 
Ritonavir -6.4 4 Asn 119(A); Glu 166(A); Cys 145(A); Thr 26(A) 
Thymoquinone -4.3 2 Gly143 (A); Thr 26(A) 




Fig. 2 — Superimposed image representing docking conformations of all ligands with COVID-19 Mpro whole complex. 




binding energies obtained and hydrogen bonds 
formed from the docking of 6LU7 in absence of C 
Chain are presented in Table 2. Ritonavir formed  
2 hydrogen bonds with -7.1 Kcal/mol of binding 
affinity. This is followed by curcumin and 
glycyrrhizin.  In terms  of both  hydrogen   bonds  and 
binding energy, ritonavir was seen to be more 
efficient compared to other compounds. The standard 
drug nelfinavir has shown-8.3 Kcal/mol of binding 
affinity with no hydrogen bonds, whereas another 
standard drug hydroxychloroquine had formed 1 
hydrogen bond with -6.3 Kcal/mole as binding energy 
which is slightly more than that of the above-
mentioned values. Fig. 5 shows the superimposition 
of all ligands with COVID-19 Mproin absence of C 
chain. Fig. 6 shows 2D interaction of ligands with 
amino acids of COVID-19 Mpro in the absence of C 
chain. Detailed hydrogen bond formation of the 
ligand with amino acids of COVID-19 Mpro whole 
complex of ligands showing best conformation 
(Curcumin, Glycyrrhizin, Piperine, Ritonavir) are 
represented in Fig. 7.  
The Catalytic dyad present between the cleft of 
domain 1 and 2 which is a   substrate-binding   site  is  
 
 
Fig. 3 — Showing 2D interaction of ligands with amino acids of COVID-19 Mpro whole complex. a) Azadirachtin,b) Beta_Sitosterol,  
c) Curcumin, d) Gingerol, e) Glycyrrhizin, f) Hydroxychloroquine, g) Lopinavir, h) Nelfinavir, i), Piperine, j) Quercetin, k) Ritonavir, l) 




Fig. 4 — Showing detailed hydrogen bond formation of a ligand with amino acids of COVID-19 Mpro whole complex. a) Curcumin,  
b) Glycyrrhizin, and c) Ritonavir. 
 





Table 2 — Showing binding energy and hydrogen bonds formed with COVID-19 Mpro (absence of C chain) and ligands. 
Ligands Affinity (Kcal/mol) H bonds H bond interaction 
Azadirachtin -5.9 - - 
Beta_Sitosterol -7.1 - - 
Curcumin -7.1 2 Ser 144(A); Gly143(A) 
Gingerol -5.7 2 His164(A); Arg188(A) 
Glycyrrhizin -8.0 1 Phe140(A) 
Hydroxychloroquine -6.3 1 Ser144(A) 
Lopinavir -7.7 - - 
Nelfinavir -8.3 - - 
Piperine -7.0 2 Cys145(A); Ser144(A) 
Quercetin -7.5 1 His163(A) 
Ritonavir -7.1 2 Gly143(A); Gln189(A) 
Thymoquinone -5.0 - - 




Fig. 5 — Superimposed image representing docking conformations of all ligands with COVID-19 Mpro (absence of C chain). 
 
 
Fig. 6 — Showing 2D interaction of ligands with amino acids of COVID-19 Mpro (absence of C chain). a) Azadirachtin,  
b) Beta_Sitosterol, c) Curcumin, d) Gingerol, e) Glycyrrhizin, f) Hydroxychloroquine, g) Lopinavir, h) Nelfinavir, i) Piperine, j) Quercetin,  
k) Ritonavir, l)Thymoquinone, and m) Ursolic acid. 




mainly composed of His41 and Cys145. Ritonavir and 
curcumin molecules showed interaction with these 
two residues. 
From the above results, it is clear that curcumin, 
glycyrrhizin, and piperine showed activity against the 
COVID-19. This can be attributed to the traditional as 
well as scientific uses of the herbals containing these 
phytoconstituents. For instance, turmeric which contains 
curcumin as major constituents possess therapeutic 
activities as an anti-diabetic, hypolipidemic, anti-
inflammatory, anti-diarrhoeal, hepatoprotective, anti-
asthmatic, and anti-cancerous drug and is widely used in 
cosmetology
21
. Curcumin has shown to alleviate 
macrophages activation and lung inflammation induced 
by influence virus
27
 and curcumin was found to inhibit 
SARS-CoV in the range of 3–10 µM
28
. 
G. glabra possesses antibacterial, antioxidant, 
antimalarial, antispasmodic, anti-inflammatory,  
anti-hyperglycemic properties, antiulcer, antiviral, 
antihepatotoxic, antifungal, and herpes simplex 
inhibitory activities
25
. In an earlier study, glycyrrhizin 
was found to be most active in inhibiting replication of 
the SARS-associated virus
29
. Prepared derivatives of 
glycyrrhizin have shown 10-fold increased anti-SARS-
CoV activity compared to glycyrrhizin. Amides of 
glycyrrhizin and conjugates of glycyrrhizin with two 
amino acid residues and a free 30-COOH function 




Piper nigrum, commonly known as black pepper is 
reported to possess antiapoptotic, antibacterial, anti-
colon toxin, antidepressant, antifungal, antidiarrhoeal, 
anti-inflammatory, antimutagenic, anti-metastatic 
activity, antioxidative, antispasmodic, antisper-
matogenic, antitumor, antithyroid, gastric ailments, 
hepatoprotective, insecticidal activity, intermittent 
 
 
Fig. 7 — Showing detailed hydrogen bond formation of a ligand with amino acids of COVID-19 Mpro whole complex. a) Curcumin,  
b) Glycyrrhizin, c) Piperine, and d) Ritonavir. 
 




fever, larvicidal activity, protection against diabetes-
induced oxidative stress, analgesic, anti-inflammatory, 
anticonvulsant, antimalarial, antifiliarial, and antifertility 
activities
22
. It is very well in accordance with the present 
results of in silico technique. 
 
Conclusion: 
6LU7 is docked with different compounds and 
compared with standard drugs prescribed so far for 
coronavirus. Docking capability was evaluated both 
during the presence and absence of C chain (peptide) 
which is present at one of the active pocket. 
According to the results obtained, ritonavir and 
curcumin were found to be more effective on 
COVID-19 than nelfinavir which is an anti-HIV drug. 
This is followed by glycyrrhizin and piperine, which 
correlates with COVID-19 as a whole complex and 
also in the absence of Chain C. This study will pave a 
way for performing more advanced experimental 
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